首页> 外文期刊>Strahlentherapie und Onkologie >Preoperative chemoradiation with or without induction oxaliplatin plus 5-fluorouracil in locally advanced rectal cancer: Long-term outcome analysis
【24h】

Preoperative chemoradiation with or without induction oxaliplatin plus 5-fluorouracil in locally advanced rectal cancer: Long-term outcome analysis

机译:局部晚期直肠癌术前有无放化疗药物奥沙利铂联合5-氟尿嘧啶的化学放疗:长期疗效分析

获取原文
获取原文并翻译 | 示例
       

摘要

Background and purpose: It has been previously reported that a short FOLFOX-4 induction significantly improves pathologic complete response in locally advanced rectal cancer (LARC) patients treated with preoperative chemoradiation (CRT). In a larger and updated patient series, we analyzed FOLFOX-4 efficacy in terms of sphincter preservation and long-term outcomes. Patients and methods: From January 1995 to December 2010, 335 LARC patients were treated with preoperative chemoradiation (4500-5040 cGy). Starting in May 2001, 207 consecutive patients additionally received induction FOLFOX-4. Surgery was performed 6 weeks (range 3-12 weeks) after chemoradiation. Results: Incidence of total tumor (63 vs. 54 %, p = 0.02) and nodal downstaging (60 vs. 43 %, p = 0.002) was significantly increased by induction FOLFOX-4. In an analysis of tumors located below 5 cm from the anal verge (n = 114, 34 %), sphincter preservation was feasible in 30 % in the FOLFOX-4 versus 13 % in the upfront CRT group (p = 0.04). Median follow-up time for the entire cohort of patients was 72.6 months (range 4-205 months). FOLFOX-4 was not associated with superior locoregional control (HR 0.88, p = 0.78), disease-free survival (HR 0.83, p = 0.55), distant metastases-free survival (HR 0.94, p = 0.81), or cancer-specific survival (HR 0.70, p = 0.15). Conclusion: Short-intense induction FOLFOX-4 significantly improves downstaging and sphincter preservation in low rectal tumors. Long-term outcomes were not improved in the FOLFOX-4 group of patients.
机译:背景与目的:先前已有报道,短暂的FOLFOX-4诱导可显着改善术前化学放射(CRT)治疗的局部晚期直肠癌(LARC)患者的病理完全反应。在更大和更新的患者系列中,我们从括约肌保留和长期预后方面分析了FOLFOX-4疗效。患者和方法:1995年1月至2010年12月,对335名LARC患者进行了术前化学放疗(4500-5040 cGy)。从2001年5月开始,连续207位患者还接受了FOLFOX-4诱导。化学放疗后6周(3-12周)进行手术。结果:诱导FOLFOX-4显着增加了总肿瘤发生率(63%vs. 54%,p = 0.02)和淋巴结分期降低(60%vs. 43%,p = 0.002)。在分析距肛门边缘5 cm以下的肿瘤(n = 114,34%)时,在FOLFOX-4中保留30%的括约肌是可行的,而在前CRT组中保留13%是可行的(p = 0.04)。整个患者队列的中位随访时间为72.6个月(范围4-205个月)。 FOLFOX-4与较高的局部区域控制(HR 0.88,p = 0.78),无病生存期(HR 0.83,p = 0.55),远处无转移生存期(HR 0.94,p = 0.81)或癌症特异性无关生存率(HR 0.70,p = 0.15)。结论:低强度诱导FOLFOX-4可以显着改善低位直肠肿瘤的降级和括约肌保留。 FOLFOX-4组患者的长期结局并未改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号